Decongestants for dilating the nasal cavity, a randomised, blinded, prospective study to prevent iatrogenic epistaxis during nasotracheal intubation

Decongestants for dilating the nasal cavity, a randomised, blinded, prospective study to prevent iatrogenic epistaxis during nasotracheal intubation - Nasal Intubation Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON41173

Enrollment

180

Registered

2014-07-16

Start date

2014-08-25

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

epistaxis nasal trauma

Interventions

Patients will receive either a nasal decongestant (xylomethazoline) combined with a polyvinyl-alcohol nasal dilator 60 minutes before nasal intubation and xylomethazoline 5 minutes before the intuba

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: o Age older than 18 years o Nasal intubation indicated and required for the planned surgery o Informed consent

Exclusion criteria

Exclusion criteria: o Age less than 18 years old o COPD Gold 3 or 4 o Severe dyspnoe o (History of) nasal trauma or anatomical deformities o Known allergy to any of the medications used

Design outcomes

Primary

Measure	Time frame
• Severity of the epistaxis • Requiring suction • Navigability of the tube during nasal passage	—

Secondary

Measure	Time frame
• Number of attempts • Resistance during intubation • Difficulty of intubation (grade of intubation) • Evaluation of nasal complications • Persistent nasal bleeding • Nasal pain (NRS-score) • Nasal trauma • Difficulty of nasal breathing	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)